Company Overview and News
Shares of ACADIA Pharmaceuticals Inc. (ACAD - Free Report) soared 26.6% after the FDAissued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis. However, shares of the company have decreased 36.5% year to date compared with the industry’s decline of 3.5%.
REGN GILD AT LGNDZ EOG ACAD ATP SRE LGNZZ LGND LGNYZ LGNXZ SPG APRWF
Exelixis, Inc. (EXEL - Free Report) along with its partner Ipsen Biopharmaceuticals Canada announced that Health Canada has approved Cabometyx (cabozantinib) tablets for the treatment of advanced renal cell carcinoma (RCC) in adult patients, previously treated with vascular endothelial growth factor targeted therapy.
WFC WFCNP EXEL GILD RHT NVS CSIQ
2018-09-20 zacks - 1
Molecular Templates, Inc. (MTEM - Free Report) announced that it has signed an agreement with Japan’s Takeda Pharmaceutical for jointly developing CD38-targeted engineered toxin antibodies (ETBs) for the treatment of multiple myeloma.
WFC WFCNP GILD PCRX BSTC MTEM
2018-09-20 investorplace - 1
One of the most popular investment strategies is to focus on fast-charging growth companies. The appeal, of course, is that you can get in on the ground floor of a paradigm-shifting industry. But remember the adage cash is king. The most dependable stocks to buy are usually what people call “cash cows.”
BCE PM AFL GILD GOOGL GOOG MCD ATVI PAYX
Chicago, IL – September 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Regeneron Pharmaceuticals (REGN - Free Report) , Celgene Corporation (CELG - Free Report) , Sanofi (SNY - Free Report) and Gilead Sciences, Inc.
REGN CELGZ GILD AMD LB VKTX FWRD SNY HPE RCKY VKTXW CELG AMWD
athenahealth, Inc. (ATHN - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ATHN given that, according to its RSI reading of 21.43, it is now in oversold territory.
LRCX GILD AMAT ATHN
Haynes International, Inc. (HAYN - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for HAYN broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
LRCX GILD AMAT HAYN
City Holding Company (CHCO - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at CHCO given that, according to its RSI reading of 29.82, it is now in oversold territory.
LRCX GILD AMAT
Select Income REIT (SIR - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for SIR broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
LRCX GILD SIR AMAT
On Assignment, Inc. (ASGN - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ASGN given that, according to its RSI reading of 26.03, it is now in oversold territory.
LRCX GILD ASGN AMAT
2018-09-20 zacks - 1
Alder BioPharmaceuticals, Inc. (ALDR - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ALDR given that, according to its RSI reading of 29.86, it is now in oversold territory.
LRCX GILD AMAT ALDR
Gilead Sciences (GILD - Free Report) closed at $73.88 in the latest trading session, marking a +0.31% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow added 0.61%, and the tech-heavy Nasdaq lost 0.08%.
GILD MLHR NXTM OMN PRGS
2018-03-04 - Asif
Overview Gilead Sciences, Inc. (Gilead, we, its or us), incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, the company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead Sciences has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. The company seek to add to its existing portfolio of products through its internal discovery and clinical development programs and through product acquisition and in-licensing strategies. 2017 Highlights Over the past year, the company continued to bring best-in-class drugs to market that advance the standard of care by off...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to GILD / Gilead Sciences, Inc. on message board site Silicon Investor.
as of ET